Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | ESR1 | P03372 | 2/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.60 |
| ▸ | MGAM | O43451 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637432 | 0.91 | ALOX5AP (0.83) | ALOX5APKDM4EMEN1MAPTKMT2A | |
| SCHEMBL26621109 | 0.90 | ALOX5AP (0.82) | ALOX5APKDM4EMEN1MAPTKMT2A | |
| SCHEMBL30005641 | 0.89 | ALOX5AP (0.80) | ALOX5APKDM4EMEN1MAPTKMT2A | |
| SCHEMBL32676365 | 0.84 | ALOX5AP (0.72) | ALOX5APKDM4EMEN1MAPTKMT2A | |
| SCHEMBL29497159 | 0.82 | ALOX5AP (0.69) | ALOX5APKDM4EMEN1MAPTKMT2A | |
| SCHEMBL15383650 | 0.82 | ALOX5AP (0.69) | ALOX5APKDM4EMEN1MAPTKMT2A | |
| Glycyrol SCHEMBL758197 | 0.79 | ALOX5AP (0.65) | ALOX5APKDM4EMEN1MAPTKMT2A | |
| Glycyrol SCHEMBL29499208 | 0.79 | ALOX5AP (0.65) | ALOX5APKDM4EMEN1MAPTKMT2A | |
| Coumestrol SCHEMBL22012 | 0.77 | ESR2 (1.00) | ALOX5APKDM4EMEN1MAPTKMT2A | |
| Coumestrol SCHEMBL29453366 | 0.77 | ESR2 (1.00) | ALOX5APKDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260041097-A1 | PLANT PRIMING COMPOSITIONS AND METHODS OF USE THEREOF | ZERO GRAVITY SOLUTIONS INC (US) | 2026-02-12 | — | — | US | claimed |
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | PLUTO INC (KR) | 2025-10-30 | — | — | US | claimed |
| US-20250213585-A1 | COMPOSITIONS AND METHODS OF A CONCOMITANT THERAPY OF ALTERNATING ELECTRIC FIELDS AND NOTCH-1 INHIBITOR | SHANGHAI INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY (CN) | 2025-07-03 | — | — | US | claimed |
| EP-4494639-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | Pluto Inc. (KR) | 2025-01-22 | — | — | EP | claimed |
| WO-2024243567-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-11-28 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| WO-2023177128-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | 주식회사 플루토 | 2023-09-21 | — | — | WO | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| US-9661857-B2 | Compositions for controlling plant parasitic nematodes | YAMASHITA THOMAS T (US) | 2017-05-30 | — | — | US | claimed |
| WO-2015081199-A1 | COMPOSITIONS AND METHODS FOR TREATING HERPESVIRUS INFECTION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-06-04 | — | — | WO | claimed |
| US-8367121-B2 | Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease | FLORIDA A & M UNIVERSITY (US) | 2013-02-05 | — | — | US | claimed |
| CN-101213980-B | Biological pesticide using psoralidin to prevent and control plant fungal diseases | SHENYANG INST OF CHEMICAL TECH | 2011-05-18 | — | — | CN | claimed |
| US-20100150895-A1 | Nutraceutical agent for attenuating the Neurodegenerative process associated with Parkinson's disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-17 | — | — | US | claimed |
| US-20080292607-A1 | Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease | MAZZIO ELIZABETH | 2008-11-27 | — | — | US | claimed |
| CN-101213980-A | Biological pesticide using psoralidin to prevent and control plant fungal diseases | SHENYANG INST OF CHEMICAL TECH (CN) | 2008-07-09 | — | — | CN | claimed |
| US-20070116779-A1 | Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease | MAZZIO ELIZABETH | 2007-05-24 | — | — | US | claimed |
| WO-2001001996-A9 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OSTEOPOROSIS | UNIV WESTERN AUSTRALIA (AU) | 2002-09-12 | — | — | WO | claimed |
| WO-2001001996-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OSTEOPOROSIS | UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2001-01-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | ALOX5AP 1616/4885KDM4E 4637/4885MEN1 1711/4885 |
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | MYOF, ALOX5, MYLK2 | ALOX5AP 6/4885KDM4E 636/4885MEN1 4605/4885 |
| US-20260041097-A1 | PLANT PRIMING COMPOSITIONS AND METHODS OF USE THEREOF | XBP1, TFEB, AOC1 | ALOX5AP 2670/4885KDM4E 307/4885MEN1 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.